Just as was true at this time of year, in 2010, and on and off since, Kenilworth misjudged the demand for its Parkinson's compound, and as a consequence, its contract manufacturer (would that be Charles Rivers Labs1? Or, is that. . . Cherokee?), cannot deliver enough -- as Merck didn't place a larger order, early enough in 2018. Consequently, the APIs -- or raw inputs -- for manufacturing the drug will not be available in sufficient quantity until 2019, now. Here's a bit from FiercePharma's Eric Palmer:
. . . .Merck is out of stock and dealing with back orders of some of its Sinemet Parkinson’s disease drug products that won't be resolved until next year. The issues have resulted from manufacturing problems at the CMO that produces the drug for Merck, and because the drugmaker badly missed its forecast for demand.. . .
So it goes. Separately, Merck also posted nice top-line data, on its two new HIV meds, as a late-breaker at IDWeek 2018, on the West Coast, early this morning. [If I can free up from litigation appearances, this afternoon, I'll write about 45's latest loss in federal court in California -- on his attempts to severely curtail TPS immigrant rules.]
~~~~~~~~~~~~~~~~~~~~~~~~
1. I should note that the CEO of Sloan Kettering, who yesterday resigned from Merck's board, has also resigned from the board of Charles Rivers. But to be clear, there is no connection (at least -- I am not aware of any) between these stories -- other than that purely random coincidence. Be excellent to one another. . . we are one month away, now. . . .
नमस्ते
No comments:
Post a Comment